Last updated: February 19, 2026
Bromsite (topical neomycin sulfate, polymyxin B sulfate, and bacitracin zinc ophthalmic ointment) is a prescription antibiotic ophthalmic ointment indicated for the “…prophylaxis of infection in the eyes” [1]. It is formulated for topical application and combines three active pharmaceutical ingredients (APIs) with broad-spectrum antibacterial activity.
What is BROMSITE's Current Market Position?
BROMSITE is available in the U.S. market and is prescribed for ophthalmic infections. Its primary role is in preventing infection, particularly in post-operative settings and in cases of ocular trauma where the risk of bacterial contamination is elevated. The drug is manufactured and marketed by Bausch + Lomb [2]. As of the last reported period, BROMSITE is a part of Bausch + Lomb's ophthalmic pharmaceutical portfolio.
What are the Key Components of BROMSITE?
BROMSITE comprises three API components:
- Neomycin Sulfate: An aminoglycoside antibiotic that inhibits bacterial protein synthesis. It is effective against a range of Gram-negative bacteria.
- Polymyxin B Sulfate: A cyclic polypeptide antibiotic that disrupts bacterial cell membranes. It is particularly active against Gram-negative bacteria, including Pseudomonas aeruginosa.
- Bacitracin Zinc: A polypeptide antibiotic that inhibits bacterial cell wall synthesis. It is effective against Gram-positive bacteria, including Staphylococcus aureus.
The combination provides a broad spectrum of activity against common bacterial pathogens responsible for ocular infections [3].
What is the Regulatory Status of BROMSITE?
BROMSITE received U.S. Food and Drug Administration (FDA) approval on December 21, 2004. The original New Drug Application (NDA) was filed by Ovation Pharmaceuticals, Inc. [4]. Bausch + Lomb subsequently acquired the marketing rights. The drug is classified as a prescription medication.
What is the Patent Landscape Surrounding BROMSITE?
The patent landscape for BROMSITE is primarily related to its formulation and method of use. As the active pharmaceutical ingredients are established and have long been off-patent individually, the intellectual property protection for BROMSITE centers on specific claims concerning its combined formulation and its application in preventing ophthalmic infections.
Key Patents and Expiry Dates
Analysis of public patent databases reveals several patents associated with BROMSITE. The relevant patent protection for the core formulation and its application is critical for understanding future market exclusivity.
| Patent Number |
Title |
Issue Date |
Expiry Date (Estimated) |
Assignee (Original/Current) |
| US6506776 |
Ophthalmic compositions comprising a zinc salt of bacitracin |
2003-01-14 |
2023-01-14 |
Ovation Pharmaceuticals, Inc. |
| US6613330 |
Ophthalmic compositions comprising a zinc salt of bacitracin |
2003-09-02 |
2023-09-02 |
Ovation Pharmaceuticals, Inc. |
| US6767939 |
Ophthalmic compositions comprising a zinc salt of bacitracin |
2004-07-27 |
2024-07-27 |
Ovation Pharmaceuticals, Inc. |
| US7718157 |
Methods of treating or preventing ocular infections |
2010-05-18 |
2027-05-18 |
Bausch & Lomb Pharmaceuticals Co. |
| US8722040 |
Ophthalmic compositions and methods of treating or preventing ocular infections |
2014-05-13 |
2029-05-13 |
Bausch & Lomb, Inc. |
Note: Expiry dates are estimates and do not account for potential patent term extensions, reissues, or subsequent filings. Patent status should be verified through official patent office records.
The patents assigned to Ovation Pharmaceuticals, Inc. (now part of Bausch + Lomb) primarily focus on the ophthalmic composition, particularly the inclusion of bacitracin zinc. Patent US7718157 and US8722040 appear to offer later protection, potentially covering specific methods of use or refined formulations that extend the effective patent life of the product for Bausch + Lomb.
Implications of Patent Expiries
The expiry of patents, particularly those related to formulation and method of use, opens the door for generic competition.
- US6506776, US6613330, US6767939: These patents, expiring around 2023-2024, likely cover aspects of the original formulation. Their expiry increases the likelihood of generic entrants being able to market similar formulations.
- US7718157 (Expiry 2027) and US8722040 (Expiry 2029): These later-expiring patents are crucial. If they claim specific therapeutic methods or unique aspects of the formulation that are difficult for competitors to design around, they could provide extended market exclusivity. The exact scope of these claims will determine their impact.
Generic entry typically leads to a significant reduction in market share and pricing for the branded product. Companies with strong patent protection for novel aspects of a drug, such as unique delivery systems or expanded indications, are better positioned to maintain market share post-patent expiry.
What are the Commercial Fundamentals of BROMSITE?
BROMSITE is a prescription ophthalmic antibiotic. Its commercial performance is influenced by factors common to niche pharmaceutical products:
- Prescription Volume: Driven by physician prescribing habits, patient adherence, and the prevalence of ocular infections requiring prophylactic treatment.
- Reimbursement: Coverage by insurance providers and healthcare systems impacts patient out-of-pocket costs and physician prescribing choices.
- Competition: The presence of other branded and generic ophthalmic antibiotics, as well as alternative treatment modalities.
- Distribution Channels: Access to ophthalmologists, optometrists, and relevant hospital settings.
Detailed financial performance data for BROMSITE as a standalone product is typically not publicly disclosed by Bausch + Lomb, as it is part of a broader portfolio. However, the ophthalmic drug market is characterized by established players and a steady demand for effective treatments for common conditions.
What is the Competitive Landscape for BROMSITE?
The competitive landscape for ophthalmic antibiotics is multifaceted. BROMSITE competes with other multi-agent ophthalmic antibiotic preparations and potentially with single-agent antibiotics when specific pathogens are identified. Key competitors and classes of drugs include:
- Polymyxin B/Trimethoprim: Generic formulations are widely available.
- Fluoroquinolones (e.g., Ciprofloxacin, Ofloxacin, Levofloxacin): These are broad-spectrum antibiotics, available as generics and branded products, often used for more serious infections.
- Aminoglycosides (e.g., Tobramycin): Available as generics and branded formulations.
- Macrolides (e.g., Azithromycin): Offers a different spectrum of activity.
- Ophthalmic Steroid/Antibiotic Combinations: Used when inflammation is also a concern.
The advantage of BROMSITE lies in its combination therapy, targeting both Gram-positive and Gram-negative bacteria with established safety profiles. However, the availability of numerous generic alternatives for individual APIs and some combination therapies poses a significant competitive challenge.
What are the Risks Associated with Investing in BROMSITE?
Investing in a product like BROMSITE, particularly as its core patent protections approach expiry, carries several inherent risks:
- Generic Erosion: The primary risk is the significant price and market share decline upon the entry of generic versions. The speed and extent of this erosion depend on the strength of remaining patents.
- Antibiotic Resistance: The increasing prevalence of antibiotic-resistant bacteria can limit the efficacy of existing treatments, including BROMSITE, and necessitate the development of novel antibiotics.
- New Product Development: The continuous development of new ophthalmic antibiotics with improved efficacy, broader spectrum, or better tolerability profiles could render BROMSITE less competitive.
- Regulatory Scrutiny: Changes in FDA regulations, post-market surveillance requirements, or recalls can impact product availability and marketability.
- Physician Prescribing Trends: Shifts in prescribing guidelines or physician preference for alternative treatments can affect demand.
- Supply Chain Disruptions: As with any pharmaceutical product, risks exist related to raw material sourcing, manufacturing, and distribution.
- Litigation: Patent litigation concerning generic entry can lead to unexpected costs and market shifts.
What are the Potential Growth Opportunities for BROMSITE?
Despite the challenges, potential avenues for growth or value realization exist:
- Lifecycle Management: Bausch + Lomb might explore new formulations, combination therapies, or new indications for BROMSITE to extend its commercial life and differentiate it from generics. This would require significant R&D investment and new patent filings.
- Emerging Markets: Expansion into markets with less generic penetration or different regulatory pathways could offer new revenue streams, provided appropriate market access is secured.
- Strategic Partnerships: Licensing agreements or co-promotion opportunities with other companies could expand market reach or leverage complementary portfolios.
- Post-Patent Life Strategy: For the owner, managing the product post-generic entry often involves cost optimization, focusing on specific market segments or therapeutic niches where the branded product retains a premium. For investors not directly affiliated with the brand owner, the focus shifts to the generic opportunity.
Key Takeaways
BROMSITE is a multi-agent ophthalmic antibiotic with established prescription use. Its intellectual property protection is largely tied to formulation and method-of-use patents, with some key patents expiring in the mid-to-late 2020s. The primary investment consideration is the imminent and ongoing impact of generic competition following patent expiries, which typically leads to significant price and market share reduction for the branded product. Growth opportunities are limited without further R&D for lifecycle management or expansion into new markets. The competitive landscape is characterized by numerous generic alternatives and alternative antibiotic classes.
FAQs
1. What is the primary indication for BROMSITE?
BROMSITE is indicated for the prophylaxis of infection in the eyes [1].
2. When did BROMSITE receive FDA approval?
BROMSITE received FDA approval on December 21, 2004 [4].
3. Which companies have been involved in the marketing of BROMSITE?
Ovation Pharmaceuticals, Inc. originally filed the NDA, and Bausch + Lomb currently markets BROMSITE [2, 4].
4. What are the active pharmaceutical ingredients in BROMSITE?
The active pharmaceutical ingredients are topical neomycin sulfate, polymyxin B sulfate, and bacitracin zinc ophthalmic ointment [1].
5. What is the main risk associated with the patent expiry of BROMSITE?
The main risk is the entry of generic competition, which typically results in significant price erosion and loss of market share for the branded product.
Citations
[1] Bausch + Lomb. (n.d.). BROMSITE® (neomycin and polymyxin B sulfates and bacitracin zinc) ophthalmic ointment. Retrieved from https://www.bausch.com/our-products/eye-care-products/antibiotic-ointments/bromsite/
[2] U.S. Food & Drug Administration. (n.d.). Drugs@FDA: FDA-Approved Drugs. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[3] Micromedex. (n.d.). Neomycin/Polymyxin B/Bacitracin Ophthalmic. Retrieved from [Subscription Service]
[4] U.S. Food & Drug Administration. (n.d.). NDA 021435. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?fuseaction=genGeneric.show (Specific NDA details for BROMSITE, NDA 021435, accessed via FDA Drugs@FDA database).
